SavedAdd your journal

Journals / E Journal of Cardiovascular Medicine / 2022 / Cilt: 10 - Sayı: 2

Cystatin C and Its Temporal Change May Predict Development and Recovery of Cardio-renal Syndrome Type 1 in Acute Heart Failure

Eser AÇIKGÖZ
Sadık Kadri AÇIKGÖZ
Murat Oğuz ÖZİLHAN
Özge Çakmak KARAASLAN
Mustafa CANDEMİR
Hüseyin Murat ÖZDEMİR
Gökhan GÖKALP
Serdar Gökhan NURKOÇ
Ajar KOÇAK
Gülbahar ÖZLEM
Pages
83–92
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Admission cystatin C [odds ratio (OR): 30.97, confidence interval (CI): 9.28-139.60, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Cardio-renal syndrome type 1 (CRS1) complicates 40% of patients hospitalized for acute decompensated heart failure (ADHF) and is associated with poor prognosis.
📊
Key Findings & Data:Factors associated with the development and recovery of CRS1 have not been completely understood, and the value of cystatin C in this context has not been studied.
💡
Conclusion & Impact:Results: Admission cystatin C [odds ratio (OR): 30.97, confidence interval (CI): 9.28-139.60, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Cardio-renal syndrome type 1 (CRS1) complicates 40% of patients hospitalized for acute decompensated heart failure (ADHF) and is associated with poor prognosis. Factors associated with the development and recovery of CRS1 have not been completely understood, and the value of cystatin C in this context has not been studied. Materials and Methods: We evaluated the predictive value of cystatin C levels at admission and 24th hour and delta cystatin C (cystatin C change in the first 24 hours of admission) in the development and reversibility of CRS1 in patients hospitalized for ADHF. One hundred ten consecutive patients hospitalized for ADHF were enrolled. Results: Admission cystatin C [odds ratio (OR): 30.97, confidence interval (CI): 9.28-139.60, p

🔖

Cite This Article

AÇIKGÖZ, E., AÇIKGÖZ, S. K., ÖZİLHAN, M. O., KARAASLAN, Ö. Ç., CANDEMİR, M., ÖZDEMİR, H. M., GÖKALP, G., NURKOÇ, S. G., KOÇAK, A., ÖZLEM, G. (2022). Cystatin C and Its Temporal Change May Predict Development and Recovery of Cardio-renal Syndrome Type 1 in Acute Heart Failure. E Journal of Cardiovascular Medicine, Cilt: 10 - Sayı: 2, 83–92. https://ajindex.com/articles/498206

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11.
  2. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-96.
  3. Soni SS, Ronco C, Katz N, et al. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 2009;28:165-74.
  4. Kellum JA, Mehta RL, Levin A, et al. development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. Clin J Am Soc Nephrol 2008;3:887- 94. Lassus JP, Nieminen MS, Peuhkurinen K, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J. 2010;31:2791-8.
  5. Cruz DN, Goh CY, Haase-Fielitz A, et al. Early biomarkers of renal injury. Congestive Heart Failure. 2010;16 Suppl 1:S25-31. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39:89-104.
  6. Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem 2015;68:57-69.
  7. Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care 2010;16:533-9.
  8. Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: an emerging biomarker in cardiovascular disease. Curr Top Med Chem 2013;13:164-79.
  9. Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation 2010;121:2117-22.
  10. Wang QP, Gu JW, Zhan XH, et al. Assessment of glomerular filtration rate by serum cystatin C in patients undergoing coronary artery bypass grafting. Ann Clin Biochem 2009;46:495-500.
  11. Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail 2009;11:354-60.
  12. Rafouli-Stergiou P, Parissis J, Farmakis D, et al. Prognostic value of inhospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. Int J Cardiol 2015;182:74-6.
  13. Garcia Acuna JM, Gonzalez-Babarro E, Grigorian Shamagian L, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol 2009;62:510-9. KDIGO Clinical Practice Guidelines for Acute Kidney Injury 2